Акромегалія. Клінічні настанови Ендокринологічного товариства (2014 р.). Частина 2

Н. Б. Зелінська

Анотація


Мета полягає в розробці практичних клінічних настанов з акромегалії.

Учасники. Цільова група складається з голови, обраного підкомітетом Ендокринологічного товариства з клінічних настанов (Clinical Guidelines Subcommittee, CGS), п’яти експертів у цій галузі і методиста. Автори не отримали корпоративного фінансування або винагороди.

Настанови розроблені у співавторстві з Європейським ендокринологічним товариством.

Доказова база. Ці настанови на основі фактичних даних розроблено з використанням принципу GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) — градації рекомендацій, оцінки та експертизи ступеня їх обґрунтованості — для опису як ступеня переконливості рекомендацій, так і якості доказової бази. Цільова група розглянула основне свідчення і два повноважних додаткових систематичних огляди.

Процес узгодження. Одна нарада групи, кілька конференц­зв’язків, а також спілкування електрон­ною поштою забезпечили досягнення консенсусу. Комітети та члени Ендокринологічного товариства, Європейського ендокринологічного товариства розглянули проекти цих керівних настанов.

Висновки. Використовуючи підхід на основі фактичних даних, ця настанова вирішує важливі клінічні питання, що стосуються визначення та управління акромегалією, зокрема відповідної біохімічної оцінки, терапевтичного алгоритму, як­то використання монотерапії або комбінованої терапії та ведення хворих під час вагітності


Повний текст:

PDF

Посилання


Abs R., Verhelst J., Maiter D. et al. Cabergoline in the treatment of acromegaly: a study in 64 patients // J. Clin. Endocrinol. Metab. — 1998. — 83. — P. 374—378.

Attanasio R., Mainolfi A., Grimaldi F. et al. Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients // J. Endocrinol. Invest. — 2008. — 31. — P. 704—710.

Barkan A.L., Burman P., Clemmons D.R. et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant // J. Clin. Endocrinol. Metab. — 2005. — 90. — P. 5684—5691.

Barrande G., Pittino-Lungo M., Coste J. et al. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center // J. Clin. Endocrinol. Metab. — 2000. — 85. — P. 3779—3785.

Beckers A., Stevenaert A., Foidart J.M. et al. Placental and pituitary growth hormone secretion during pregnancy in acromegalic women // J. Clin. Endocrinol. Metab. — 1990. — 71. — P. 725—731.

Bernabeu I., Alvarez-Escolá C., Paniagua A.E. et al. Pegvisomant and cabergoline combination therapy in acromegaly // Pituitary. — 2013. — 16. — P. 101—108.

Bernabeu I., Marazuela M., Lucas T. et al. Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert’s synd­­rome // J. Clin. Endocrinol. Metab. — 2010. — 95. — P. 2147—2154.

Bevan J.S., Newell-Price J., Wass J.A. et al. Home administration of lanreotide autogel by patients with acromegaly, or their partners, is safe and effective // Clin. Endocrinol. (Oxf). — 2008. — 68. — P. 343—349.

Bhayana S., Booth G.L., Asa S.L. et al. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acro­­megaly // J. Clin. Endocrinol. Metab. — 2005. — 90. — P. 6290—6295.

Biermasz N.R., Dulken H.V., Roelfsema F. Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels // Clin. Endocrinol. (Oxf). — 2000. — 53. — P. 321—327.

Biermasz N.R., van Dulken H., Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly // J. Clin. Endocrinol. Metab. — 2000. — 85. — P. 2476—2482.

Bonert V.S., Kennedy L., Petersenn S. et al. Lipodystrophy in patients with acromegaly receiving pegvisomant // J. Clin. Endocrinol. Metab. — 2008. — 93. — P. 3515—3518.

Brian S.R., Bidlingmaier M., Wajnrajch M.P. et al. Treatment of acro­­me­­galy with pegvisomant during pregnancy: maternal and fetal effects // J. Clin. Endocrinol. Metab. — 2007. — 92. — P. 3374—3377.

Buhk J.H., Jung S., Psychogios M.N. et al. Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study // J. Clin. Endocrinol. Metab. — 2010. — 95. — P. 552—558.

Cappabianca P., Cavallo L.M., Colao A., de Divitiis E. Surgical complications associated with the endoscopic endonasal trans­sphe­noidal approach for pituitary adenomas // J. Neurosurg. — 2002. — 97. — P. 293—298.

Carlsen S.M., Lund-Johansen M., Schreiner T. et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial // J. Clin. Endocrinol. Metab. — 2008. — 93. — P. 2984—2990.

Carmichael J.D., Bonert V.S., Mirocha J.M., Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly // J. Clin. Endocrinol. Metab. — 2009. — 94. — P. 523—527.

Caron P., Bex M., Cullen D.R. et al. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide autogel // Clin. Endocrinol. (Oxf). — 2004. — 60. — P. 734—740.

Caron P., Broussaud S., Bertherat J. et al. Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women // J. Clin. Endocrinol. Metab. — 2010. — 95. — P. 4680—4687.

Caron P.J., Bevan J.S., Petersenn S. et al. Tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial // J. Clin. Endocrinol. Metab. — 2014. — 99. — P. 1282—1290.

Castinetti F., Morange I., Dufour H. et al. Radiotherapy and radiosurgery in acromegaly // Pituitary. — 2009. — 12. — P. 3—10.

Castinetti F., Nagai M., Morange I. et al. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas // J. Clin. Endocrinol. Metab. — 2009. — 94. — P. 3400—3407.

Castinetti F., Taieb D., Kuhn J.M. et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion // J. Clin. Endocrinol. Metab. — 2005. — 90. — P. 4483—4488.

Chen W.Y., Wight D.C., Wagner T.E., Kopchick J.J. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice // Proc. Natl. Acad. Sci. USA. — 1990. — 87. — P. 5061—5065.

Cheng S., Grasso L., Martinez-Orozco J.A. et al. Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature // Clin. Endocrinol. (Oxf). — 2012. — 76. — P. 264—271.

Cheng V., Faiman C., Kennedy L. et al. Pregnancy and acromegaly: a review // Pituitary. — 2012. — 15. — P. 59—63.

Colao A., Attanasio R., Pivonello R. et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly // J. Clin. Endocrinol. Metab. — 2006. — 91. — P. 85—92.

Colao A., Bronstein M.D., Freda P. et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study // J. Clin. Endocrinol. Metab. — 2014. — 99. — P. 791—799.

Colao A., Pivonello R., Auriemma R.S. et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients // J. Clin. Endocrinol. Metab. — 2006. — 91. — P. 2112—2118.

Cozzi R., Attanasio R., Barausse M. Pregnancy in acromegaly: a one-center experience // Eur. J. Endocrinol. — 2006. — 155. — P. 279—284.

Cozzi R., Montini M., Attanasio R. et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage // J. Clin. Endocrinol. Metab. — 2006. — 91. — P. 1397—1403.

Damjanovic S.S., Neskovic A.N., Petakov M.S. et al. High output heart failure in patients with newly diagnosed acromegaly // Am. J. Med. — 2002. — 112. — P. 610—616.

Dina T.S., Feaster S.H., Laws E.R. Jr, Davis D.O. MR of the pituitary gland postsurgery: serial MR studies following transsphenoidal resection // Am. J. Neuroradiol. — 1993. — 14. — P. 763—769.

Erfurth E.M., Bülow B., Mikoczy Z. et al. Is there an increase in second brain tumours after surgery and irradiation for a pituitary tumour? // Clin. Endocrinol. (Oxf). — 2001. — 55. — P. 613—616.

Eriksson L., Frankenne F., Edèn S. et al. Growth hormone 24-h serum profiles during pregnancy-lack of pulsatility for the secretion of the placental variant // Br. J. Obstet. Gynaecol. 1989. — 96. — P. 949—953.

Eugster E.A., Pescovitz O.H. Gigantism // J. Clin. Endocrinol. Metab. — 1999. — 84. — P. 4379—4384.

Ezzat S., Kontogeorgos G., Redelmeier D.A. et al. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide // Eur. J. Endocrinol. — 1995. — 133. — P. 686—690.

Filopanti M., Barbieri A.M., Mantovani G. et al. Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patients // Eur. J. Endocrinol. — 2014. — 170. — P. 247—254.

Fleseriu M. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review // Pituitary. — 2011. — 14. — P. 184—193.

Frankenne F., Closset J., Gomez F. The physiology of growth hormones (GHs) in pregnant women and partial characterization of the placental GH variant // J. Clin. Endocrinol. Metab. — 1988. — 66. — P. 1171—1980.

Freda P.U. Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? // Clin. Endocrinol. (Oxf). — 2009. — 71. — P. 166—170.

Freda P.U., Katznelson L., van der Lely A.J. et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis // J. Clin. Endocrinol. Metab. — 2005. — 90. — P. 4465—4473.

Freda P.U., Nuruzzaman A.T., Reyes C.M. et al. Significance of «abnormal» nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels // J. Clin. Endocrinol. Metab. — 2004. — 89. — P. 495—500.

Freda P.U., Reyes C.M., Nuruzzaman A.T. et al. Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors // Pituitary. — 2004. — 7. — P. 21—30.

Friedel M.E., Johnston D.R., Singhal S. et al. Airway management and perioperative concerns in acromegaly patients undergoing endoscopic transsphenoidal surgery for pituitary tumors // Otolaryngol Head Neck Surg. — 2013. — 149. — P. 840—844.

Frohman L.A., Bonert V. Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy // Pituitary. — 2007. — 10. — P. 283—289.

Giustina A., Bonadonna S., Bugari G. et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial // Eur. J. Endocrinol. — 2009. — 161. — P. 331—338.

Giustina A., Mazziotti G., Torri V. et al. Meta-analysis on the effects of octreotide on tumor mass in acromegaly // PLoS One. — 2012. — 7. — P. e36411.

Goldenberg N., Racine M.S., Thomas P. et al. Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant // J. Clin. Endocrinol. Metab. — 2008. — 93. — P. 2953—2956.

Herman-Bonert V., Seliverstov M., Melmed S. Pregnancy in acromegaly: successful therapeutic outcome // J. Clin. Endocrinol. Metab. — 1998. — 83. — P. 727—731.

Higham C.E., Atkinson A.B., Aylwin S. et al. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial // J. Clin. Endocrinol. Metab. — 2012. — 97. — P. 1187—1193.

Howlett T.A., Willis D., Walker G. et al. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists // Clin. Endocrinol. (Oxf). — 2013. — 79. — P. 689—699.

Hradec J., Kral J., Janota T. et al. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog) // Am. J. Cardiol. — 1999. — 83. — P. 1506—1509, A8.

Jallad R.S., Musolino N.R., Salgado L.R., Bronstein M.D. Treatment of acromegaly: is there still a place for radiotherapy? // Pituitary. — 2007. — 10. — P. 53—59.

Jane J.A. Jr, Starke R.M., Elzoghby M.A. et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome // J. Clin. Endocrinol. Metab. — 2011. — 96. — P. 2732—2740.

Jenkins P.J., Bates P., Carson M.N. et al. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly // J. Clin. Endocrinol. Metab. — 2006. — 91. — P. 1239—1245.

Jezková J., Marek J., Hána V. et al. Gamma knife radiosurgery for acromegaly-long-term experience // Clin. Endocrinol. (Oxf).— 2006. — 64. — P. 588—595.

Jørgensen J.O., Feldt-Rasmussen U., Frystyk J. et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist // J. Clin. Endocrinol. Metab. — 2005. — 90. — P. 5627—5631.

Karavitaki N., Turner H.E., Adams C.B. et al. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide // Clin. Endocrinol. (Oxf). — 2008. — 68. — P. 970—975.

Kasuki L., Neto L.V., Takiya C.M., Gadelha M.R. Growth of an aggressive tumor during pregnancy in an acromegalic patient // Endocr. J. — 2012. — 59. — P. 313—319.

Katznelson L. Pegvisomant for the treatment of acromegaly-translation of clinical trails into clinical practice // Nat. Clin. Pract. Endocrinol. Metab. — 2007. — 3. — P. 514—515.

Katznelson L., Atkinson J.L., Cook D.M. et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update // Endocr. Pract. — 2011. — 17 (Suppl. 4). — P. 1—44.

Khan Z.H., Rasouli M.R. Intubation in patients with acromegaly: experience in more than 800 patients // Eur. J. Anaesthesiol. — 2009. — 26. — P. 354—355.

Kim E.H., Oh M.C., Lee E.J., Kim S.H. Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly // Neurosurgery. — 2012. — 70. — P. 1106—1113. — Discussion 1113.

Kiseljak-Vassiliades K., Shafi S., Kerr J.M. et al. Clinical implications of growth hormone-secreting tumor subtypes // Endocrine. — 2012. — 42. — P. 18—28.

Kopchick J.J., Parkinson C., Stevens E.C., Trainer P.J. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly // Endocr. Rev. — 2002. — 23. — P. 623—646.

Kreutzer J., Vance M.L., Lopes M.B., Laws E.R. Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria // J. Clin. Endocrinol. Metab. — 2001. — 86. — P. 4072—4077.

Krieger M.D., Couldwell W.T., Weiss M.H. Assessment of long-term remission of acromegaly following surgery // J. Neurosurg. — 2003. — 98. — P. 719—724.

Kupersmith M.J., Rosenberg C., Kleinberg D. Visual loss in pregnant women with pituitary adenomas // Ann. Intern. Med. — 1994. — 121. — P. 473—477.

Landolt A.M., Haller D., Lomax N. et al. Octreotide may act as a radioprotective agent in acromegaly // J. Clin. Endocrinol. Metab. — 2000. — 85. — P. 1287—1289.

Laws E.R., Sheehan J.P., Sheehan J.M. et al. Stereotactic radiosurgery for pituitary adenomas: a review of the literature // J. Neurooncol. — 2004. — 69. — P. 257—272.

Lee C.C., Vance M.L., Xu Z. et al. Stereotactic radiosurgery for acro­­megaly // J. Clin. Endocrinol. Metab. — 2014. — 99. — P. 1273—1281.

Levy M.J. The association of pituitary tumors and headache // Curr. Neurol. Neurosci. Rep. — 2011. — 11. — P. 164—170.

Lombardi G., Colao A., Marzullo P. et al. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study // J. Endocrinol. Invest. — 2002. — 25. — P. 971—976.

Maffei P., Tamagno G., Nardelli G.B. et al. Effects of octreotide exposure during pregnancy in acromegaly // Clin. Endocrinol. (Oxf). — 2010. — 72. — P. 668—677.

Maheshwari H.G., Prezant T.R., Herman-Bonert V. et al. Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma // J. Clin. Endocrinol. Metab. — 2000. — 85. — P. 3409—3416.

Maione L., Garcia C., Bouchachi A. et al. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly // J. Clin. Endocrinol. Metab. — 2012. — 97. — P. E1714—E1719.

Mao Z.G., Zhu Y.H., Tang H.L. et al. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial // Eur. J. Endocrinol. — 2010. — 162. — P. 661—666.

Marazuela M., Paniagua A.E., Gahete M.D. et al. Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study // J. Clin. Endocrinol. Metab. — 2011. — 96. — P. E251—E259.

McLaughlin N., Laws E.R., Oyesiku N.M. et al. Pituitary centers of excellence // Neurosurgery. — 2012. — 71. — P. 916—924. — discussion 924—926.

Meij B.P., Lopes M.B., Ellegala D.B. et al. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery // J. Neurosurg. — 2002. — 96. — P. 195—208.

Melmed S. Acromegaly pathogenesis and treatment // J. Clin. Invest. — 2009. — 119. — P. 3189—3202.

Melmed S. Medical progress: acromegaly // N. Engl. J. Med. — 2006. — 355. — P. 2558—2573.

Melmed S., Braunstein G.D., Horvath E. et al. Pathophysiology of acromegaly // Endocr. Rev. — 1983. — 4. — P. 271—290.

Melmed S., Colao A., Barkan A. et al. Guidelines for acromegaly management: an update // J. Clin. Endocrinol. Metab. — 2009. — 94. — P. 1509—1517.

Melmed S., Cook D., Schopohl J. et al. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension // Pituitary. — 2010. — 13. — P. 18—28.

Mercado M., Borges F., Bouterfa H. et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly // Clin. Endocrinol. (Oxf). — 2007. — 66. — P. 859—868.

Mestron A., Webb S.M., Astorga R. et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acro­­megalia, REA) // Eur. J. Endocrinol. — 2004. — 151. — P. 439—446.

Minniti G., Jaffrain-Rea M.L., Osti M. et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas // Clin. Endocrinol. (Oxf.). — 2005. — 62. — P. 210—216.

Minniti G., Traish D., Ashley S. et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years // J. Clin. Endocrinol. Metab. — 2005. — 90. — P. 800—804.

Molitch M.E. Prolactinoma in pregnancy // Best Pract. Res. Clin. Endocrinol. Metab. — 2011. — 25. — P. 885—896.

Molitch M.E., Grossman A.B. Pituitary radiotherapy // Pituitary. — 2009. — 12. — P. 1—2.

Muller A.F., Kopchick J.J., Flyvbjerg A., van der Lely A.J. Clinical review 166: growth hormone receptor antagonists // J. Clin. Endocrinol. Metab. — 2004. — 89. — P. 1503—1511.

Murray R.D., Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly // J. Clin. Endocrinol. Metab. — 2008. — 93. — P. 2957—2968.

Müssig K., Gallwitz B., Honegger J. et al. Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma // Exp. Clin. Endocrinol. Diabetes. — 2007. — 115. — P. 198—202.

Neggers S.J., de Herder W.W., Feelders R.A., van der Lely A.J. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients // Pituitary. — 2011. — 14. — P. 253—258.

Neggers S.J., de Herder W.W., Janssen J.A. et al. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients // Eur. J. Endocrinol. — 2009. — 160. — P. 529—533.

Neggers S.J., van Aken M.O., de Herder W.W. et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant // J. Clin. Endocrinol. Metab. — 2008. — 93. — P. 3853—3859.

Nemergut E.C., Dumont A.S., Barry U.T., Laws E.R. Perioperative management of patients undergoing transsphenoidal pituitary surgery // Anesth. Analg. — 2005. — 101. — P. 1170—1181.

Noad R., Narayanan K.R., Howlett T. et al. Evaluation of the effect of radiotherapy for pituitary tumours on cognitive function and quality of life // Clin. Oncol. (R. Coll. Radiol). — 2004. — 16. — P. 233—237.

Nomikos P., Buchfelder M., Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’ // Eur. J. Endocrinol. — 2005. — 152. — P. 379—387.

Nosé V., Ezzat S., Horvath E. et al. Protocol for the examination of specimens from patients with primary pituitary tumors // Arch. Pathol. Lab. Med. — 2011. — 135. — P. 640—646.

Okada Y., Morimoto I., Ejima K. et al. A case of active acromegalic woman with a marked increase in serum insulin-like growth factor-1 levels after delivery // Endocr. J. — 1997. — 44. — P. 117—120.

Paisley A.N., Roberts M.E., Trainer P.J. Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems // Clin. Endocrinol. (Oxf.). — 2007. — 66. — P. 723—726.

Peace K.A., Orme S.M., Padayatty S.J. et al. Cognitive dysfunction in patients with pituitary tumour who have been treated with transfrontal or transsphenoidal surgery or medication // Clin. Endocrinol. (Oxf.). — 1998. — 49. — P. 391—396.

Petrossians P., Borges-Martins L., Espinoza C. et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs // Eur. J. Endocrinol. — 2005. — 152. — P. 61—66.

Plöckinger U., Bäder M., Hopfenmüller W. et al. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology // Eur. J. Endocrinol. — 1997. — 136. — P. 369—376.

Pokrajac A., Claridge A.G., Shakoor S.K., Trainer P.J. The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly // Eur. J. Endocrinol. — 2006. — 154. — P. 267—274.

Pollock B.E., Jacob J.T., Brown P.D., Nippoldt T.B. Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission // J. Neurosurg. — 2007. — 106. — P. 833—838.

Pollock B.E., Kondziolka D., Lunsford L.D., Flickinger J.C. Stereotactic radiosurgery for pituitary adenomas: imaging, visual and endocrine results // Acta. Neurochir. Suppl. — 1994. — 62. — P. 33—38.

Pollock B.E., Nippoldt T.B., Stafford S.L. et al. Results of stereotac­­tic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalization // J. Neurosurg. — 2002. — 97. — P. 525—530.

Powell J.S., Wardlaw S.L., Post K.D., Freda P.U. Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure // J. Clin. Endocrinol. Metab. — 2000. — 85. — P. 2068—2071.

Puig-Domingo M., Resmini E., Gomez-Anson B. et al. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure // J. Clin. Endocrinol. Metab. — 2010. — 95. — P. 973—4978.

Rieger A., Rainov N.G., Ebel H. et al. Factors predicting pituitary adenoma invasiveness in acromegalic patients // Neurosurg. Rev. — 1997. — 20. — P. 182—187.

Rix M., Laurberg P., Hoejberg A.S., Brock-Jacobsen B. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl // Eur. J. Endocrinol. — 2005. — 153. — P. 195—201.

Ronchi C.L., Attanasio R., Verrua E. et al. Efficacy and tolerability of gamma knife radiosurgery in acromegaly: a 10-year follow-up study // Clin. Endocrinol. (Oxf.). — 2009. — 71. — P. 846—852.

Rowe J., Grainger A., Walton L. et al. Risk of malignancy after gamma knife stereotactic radiosurgery // Neurosurgery. — 2007. — 60. — P. 60—65. — Discussion 65—66.

Salvatori R., Woodmansee W.W., Molitch M. et al. Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry // Pituitary. — 2014. — 17. — P. 13—21.

Sandret L., Maison P., Chanson P. Place of cabergoline in acromegaly: a meta-analysis // J. Clin. Endocrinol. Metab. — 2011. — 96. — P. 1327—1335.

Schopohl J., Strasburger C.J., Caird D. et al. Efficacy and acceptability of lanreotide autogel 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR // Exp. Clin. Endocrinol. Diabetes. — 2011. — 119. — P. 156—162.

Schreiber I., Buchfelder M., Droste M. et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study // Eur. J. Endocrinol. — 2007. — 156. — P. 75—82.

Seidman P.A., Kofke W.A., Policare R., Young M. Anaesthetic complications of acromegaly // Br. J. Anaesth. — 2000. — 84. — P. 179—182.

Shen M., Shou X., Wang Y. et al. Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study // Endocr. J. — 2010. — 57. — P. 1035—1044.

Starke R.M., Raper D.M., Payne S.C. et al. Endoscopic vs micro­surgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission // J. Clin. Endocrinol. Metab. — 2013. — 98. — P. 3190—3198.

Trainer P.J., Drake W.M., Katznelson L. et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant // N. Engl. J. Med. — 2000. — 342. — P. 1171—1177.

Trainer P.J., Ezzat S., D’Souza G.A. et al. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly // Clin. Endocrinol. (Oxf.). — 2009. — 71. — P. 549—557.

Tuvia S., Atsmon J., Teichman S.L. et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression // J. Clin. Endocrinol. Metab. — 2012. — 97. — P. 2362—2369.

Valassi E., Klibanski A., Biller B.M. Clinical review#: potential cardiac valve effects of dopamine agonists in hyperprolactinemia // J. Clin. Endocrinol. Metab. — 2010. — 95. — P. 1025—1033.

Van der Lely A.J., Biller B.M., Brue T. et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY // J. Clin. Endocrinol. Metab. — 2012. — 97. — P. 1589—1597.

Van der Lely A.J., Hutson R.K., Trainer P.J. et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist // Lancet. — 2001. — 358. — P. 1754—1759.

Wass J.A., Turner H.E., Adams C.B. The importance of locating a good pituitary surgeon // Pituitary. — 1999. — 2. — P. 51—54.

Wilson T.J., McKean E.L., Barkan A.L. et al. Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications // Pituitary. — 2013. — 16. — P. 459—464.

Wolfsberger S., Knosp E. Comments on the WHO 2004 classification of pituitary tumors // Acta. Neuropathol. — 2006. — 111. — P. 66—67.

Yamada S., Fukuhara N., Oyama K. et al. Repeat transsphenoidal surgery for the treatment of remaining or recurring pituitary tumors in acromegaly // Neurosurgery. — 2010. — 67. — P. 949—956.

Zada G., Cavallo L.M., Esposito F. et al. Transsphenoidal surgery in patients with acromegaly: operative strategies for overcoming technically challenging anatomical variations // Neurosurg. Focus. — 2010. — 29. — P. E8.


Посилання

  • Поки немає зовнішніх посилань.



Видавнича група «ВІТ-А-ПОЛ»